Role for Paxlovid in Younger COVID Patients With Serious Comorbidities

(MedPage Today) -- The benefit of nirmatrelvir-ritonavir (Paxlovid) for high-risk COVID-19 outpatients appears to extend to younger vaccinated adults with serious comorbidities, retrospective data suggested. In a propensity-score matched analysis...
Source: MedPage Today Infectious Disease - Category: Infectious Diseases Source Type: news